Mallinckrodt, Depomed rise on FDA priority review for MNK-795 in pain
This article was originally published in Scrip
Executive Summary
Investors drove shares of Mallinckrodt up 3.6% in morning trading on 29 July after the firm disclosed its new drug application (NDA) for its investigational pain drug MNK-795 was accepted by the US FDA and granted a priority review.